Tiotropium formulations and safety: a network meta-analysis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Therapeutic Advances in Drug Safety

• Publication date

  2017-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/2042098616667304PMID 28203364PMCID PMC5298465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment

  2017cited by this paper
• The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease

  2016cited by this paper
• Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis

  2016cited by this paper
• A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.

  2016cited by this paper
• Tiotropium Respimat Soft Mist Inhaler versus HandiHaler to improve sleeping oxygen saturation and sleep quality in COPD

  2016influential reference
• Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis

  2015influential reference
• The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.

  2015influential reference
• Inhaled medication: which device for which patient?

  2015cited by this paper
• Regulator of G-protein signaling 6 (RGS6) in cardiology and oncology.

  2015cited by this paper
• The risk of tachyarrhythmias in patients with moderate-to-severe chronic kidney disease receiving tiotropium bromide.

  2015cited by this paper
• A primer on network meta-analysis with emphasis on mental health

  2015cited by this paper
• Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.

  2015influential reference
• Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial

  2015cited by this paper
• Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial

  2015cited by this paper
• Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial

  2015cited by this paper
• Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial

  2014influential reference
• M3 muscarinic acetylcholine receptor in cardiology and oncology.

  2014cited by this paper
• Tiotropium versus placebo for chronic obstructive pulmonary disease.

  2014cited by this paper
• Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials

  2014cited by this paper
• Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease

  2014influential reference
• Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?

  2014cited by this paper
• Retrieving Clinical Evidence: A Comparison of PubMed and Google Scholar for Quick Clinical Searches

  2013cited by this paper
• Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease

  2013cited by this paper
• Tiotropium Respimat inhaler and the risk of death in COPD.

  2013cited by this paper
• Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.

  2013cited by this paper
• Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD

  2013cited by this paper
• Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial.

  2013cited by this paper
• Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

  2012cited by this paper
• Automating network meta‐analysis

  2012cited by this paper
• Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

  2012cited by this paper
• Tiotropium versus placebo for chronic obstructive pulmonary disease.

  2012cited by this paper
• Statin use and the risk of bladder cancer: a population-based case–control study

  2012cited by this paper
• Tiotropium Bromide Inhalation Powder

  2012cited by this paper
• The clinic efficacy of tiotropium in patients with mild to moderate COPD

  2011cited by this paper
• Safety of tiotropium

  2011cited by this paper
• Overexpression of M3 Muscarinic Receptor Is a Novel Strategy for Preventing Sudden Cardiac Death in Transgenic Mice

  2011cited by this paper
• Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

  2011cited by this paper
• Cardiovascular safety of tiotropium in patients with COPD.

  2010cited by this paper
• Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.

  2010influential reference
• The cardiovascular risk of tiotropium: is it real?

  2010cited by this paper
• A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.

  2009cited by this paper
• Improvements with tiotropium in COPD patients with concomitant asthma.

  2008cited by this paper
• A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

  2008cited by this paper
• Tiotropium and exercise training in COPD patients: Effects on dyspnea and exercise tolerance

  2008influential reference
• Tiotropium improves FEV1 in patients with COPD irrespective of smoking status.

  2008influential reference
• Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD

  2008influential reference
• A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.

  2008influential reference
• Efficacy of Tiotropium Inhalation Powder in African-American Patients with Chronic Obstructive Pulmonary Disease

  2008cited by this paper
• Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD.

  2008cited by this paper
• A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

  2008influential reference
• Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

  2008cited by this paper
• Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study

  2007cited by this paper
• A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease.

  2007cited by this paper
• Function of cardiac M3 receptors.

  2007cited by this paper
• A dose-ranging study of tiotropium delivered via Respimat® Soft MistTM Inhaler or HandiHaler® in COPD patients

  2007influential reference
• Improvements with tiotropium in COPD patients with concomitant asthma

  2007influential reference
• Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD

  2007influential reference
• The Effect of Tiotropium on Hyperinflation and Exercise Capacity in Chronic Obstructive Pulmonary Disease

  2006influential reference
• Wirksamkeit von Tiotropiumbromid (Spiriva®) bei verschiedenen Schweregraden der chronisch-obstruktiven Lungenerkrankung (COPD)

  2006cited by this paper
• The effect of tiotropium on exacerbations and airflow in patients with COPD.

  2006influential reference
• Efficacy of tiotropium bromide (Spiriva®) in patients with chronic obstructive pulmonary disease (COPD) of different severities

  2006influential reference
• Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

  2005cited by this paper
• Absence of Electrocardiographic Findings and Improved Function with Once‐Daily Tiotropium in Patients with Chronic Obstructive Pulmonary Disease

  2005influential reference
• Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.

  2005influential reference
• IMPROVEMENT IN EXERCISE TOLERANCE WITH THE COMBINATION OF TIOTROPIUM AND PULMONARY REHABILITATION IN PATIENTS WITH COPD

  2005cited by this paper
• Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator

  2005influential reference
• Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD

  2004cited by this paper
• Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD

  2004cited by this paper
• Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

  2003cited by this paper
• Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.

  2003cited by this paper
• Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease

  2003influential reference
• Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

  2003influential reference
• A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.

  2002influential reference
• A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

  2002cited by this paper
• International Journal of Copd Dovepress Dovepress Efficacy and Safety of Tiotropium Respimat ® Smi in Copd in Two 1-year Randomized Studies

  year unknowncited by this paper

• Inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review and meta-analysis on mortality protection - making a long story short

  2025cites this paper
• Challenges and Opportunities in COPD Management in Latin America: A Review of Inhalation Therapies and Advanced Drug Delivery Systems

  2024cites this paper
• Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023

  2024cites this paper
• Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022

  2023cites this paper
• Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

  2023cites this paper
• Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review.

  2021cites this paper
• Association of tiotropium use and the risk of adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials

  2020cites this paper
• Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists

  2020cites this paper
• Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits

  2020cites this paper
• Aerosols in pharmaceutical product development

  2020cites this paper
• Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

  2019cites this paper
• Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease

  2019cites this paper
• Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine

  2019cites this paper
• Critical interpretation of pairwise and network meta-analysis of randomized respiratory clinical trials

  2019cites this paper
• Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis

  2019cites this paper
• Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis

  2019cites this paper
• Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.

  2019cites this paper
• Cardiovascular Disease in Chronic Respiratory Disorders and Beyond.

  2019cites this paper
• Pharmacology and Therapeutics of Bronchodilators Revisited

  2019influential citation
• Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis.

  2018cites this paper
• LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

  2018influential citation
• Combining Dual Bronchodilation and β-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases.

  2018cites this paper
• Efficacy and safety profile of xanthines in COPD: a network meta-analysis

  2018cites this paper
• LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

  2018influential citation
• A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD

  2018influential citation
• Safety of inhaled long-acting anti-muscarinic agents in COPD

  2017cites this paper
• Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis

  2017cites this paper
• The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

  2017cites this paper
• The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis

  2017cites this paper
• Optimizing drug delivery in COPD: The role of inhaler devices.

  2017cites this paper
• Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases

  2017cites this paper
• Pharmacological treatments in asthma‐affected horses: A pair‐wise and network meta‐analysis

  2017cites this paper